EE457 Long-Term Cost Effectiveness of Mavacamten for Treatment of Hypertrophic Obstructive Cardiomyopathy (HOCM)

Mavacamten is a first-in-class cardiac myosin modulator for HOCM, which genetic disorder of the sarcomere. This study assessed cost effectiveness mavacamten in addition to standard care (SoC) compared with SoC alone, as well disopyramide, myectomy, and septal ablation each SoC. A semi-Markov model was used over lifetime time horizon from healthcare sector perspective cycle length 4 weeks. Patient utilities were estimated via New York Heart Association functional classes (NYHA) but assuming mortality same across all classes. Evidence clinical trials, related literature expert experience basis inputs. placeholder price ($75,000/year) estimates. Both costs outcomes discounted at rate 3%. Cost per quality adjusted life year (QALY) gained, (LY) equal value LY gained (evLYG), additional NYHA class I interest. Sensitivity scenario analyses conducted test robustness model. In comparison alone disopyramide (with SoC), cost/QALY by $1.2 $1.5 million respectively. Compared myectomy ablation, resulted fewer QALYs, slightly more LYs incremental $5.6 $7 produced years $200,000/NYHA year. results supported findings. The actual cost-effectiveness will depend on its price. At price, ratios are beyond threshold levels. Also, dominated reduction procedures terms QALYs.